IDEXX Laboratories Files 8-K on Officer Changes and Shareholder Votes
Ticker: IDXX · Form: 8-K · Filed: May 10, 2024 · CIK: 874716
| Field | Detail |
|---|---|
| Company | Idexx Laboratories Inc /De (IDXX) |
| Form Type | 8-K |
| Filed Date | May 10, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.10, $25,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, board-of-directors, shareholder-vote
Related Tickers: IDXX
TL;DR
IDEXX leadership shuffle and shareholder votes reported in 8-K.
AI Summary
IDEXX Laboratories, Inc. filed an 8-K on May 10, 2024, reporting events as of May 6, 2024. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. It also includes the submission of matters to a vote of security holders and financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate governance events and does not indicate immediate financial distress or significant operational changes.
Key Players & Entities
- IDEXX LABORATORIES INC /DE (company) — Registrant
- May 6, 2024 (date) — Earliest event reported
- May 10, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific officer positions were affected by the departures or appointments?
The filing indicates "Departure of Directors or Certain Officers" and "Appointment of Certain Officers" but does not specify the exact positions in the provided text.
Were there any significant changes in the board of directors?
The filing mentions "Election of Directors" as an item covered, suggesting potential changes to the board.
What were the key matters submitted to a vote of security holders?
The filing states "Submission of Matters to a Vote of Security Holders" but does not detail the specific matters in the provided text.
Are the financial statements and exhibits filed with this 8-K significant?
The filing lists "Financial Statements and Exhibits" as an item, but their significance would require reviewing the actual documents attached to the filing.
What is the primary business of IDEXX Laboratories, Inc. according to the filing?
The filing lists the Standard Industrial Classification as "IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]" and the organization name as "Life Sciences."
Filing Stats: 823 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2024-05-10 16:00:23
Key Financial Figures
- $0.10 — ange on which registered Common Stock, $0.10 par value per share IDXX NASDAQ Global
- $25,000 — loyees and will receive compensation of $25,000 per month (the "Consulting Fees"). The
Filing Documents
- idxx-20240506.htm (8-K) — 51KB
- exhibit101-jpconsultingagr.htm (EX-10.1) — 61KB
- idxx-20240506_g1.jpg (GRAPHIC) — 47KB
- 0000874716-24-000107.txt ( ) — 386KB
- idxx-20240506.xsd (EX-101.SCH) — 2KB
- idxx-20240506_def.xml (EX-101.DEF) — 15KB
- idxx-20240506_lab.xml (EX-101.LAB) — 26KB
- idxx-20240506_pre.xml (EX-101.PRE) — 15KB
- idxx-20240506_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On May 6, 2024, the Company held its 2024 annual meeting of shareholders (the "Annual Meeting"). At the Annual Meeting, shareholders considered and voted on the following proposals, each of which is described in more detail in the Company's proxy statement dated March [27], 2024, (the "Proxy Statement"): (1) the election of Irene Chang Britt, Bruce L. Claflin, Asha S. Collins, PhD and Sam Samad, each as a Class I director, for terms expiring at the 2027 annual meeting of shareholders; (2) the ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered accounting firm for the current fiscal year; (3) the approval, on an advisory basis, of the compensation of the Company's named executive officers; and (4) a shareholder proposal regarding simple majority vote as presented in the Company's proxy statement delivered to shareholders in connection with the Annual Meeting. The voting results at the Annual Meeting with respect to each of the matters described above, were as follows: Proposal One: Election of Directors. Nominees For Against Abstain Broker Non-Votes Irene Chang Britt 68,830,275 114,870 190,892 5,462,716 Bruce L. Claflin 64,539,198 4,403,367 193,562 5,462,716 Asha S. Collins, PhD 67,054,357 1,892,248 189,432 5,462,716 Sam Samad 65,193,479 3,748,617 193,941 5,462,716 Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm. For 70,547,786 Against 3,857,651 Abstain 193,316 Broker Non-Votes N/A Proposal Three: Advisory Vote to Approve Executive Compensation. For 64,265,443 Against 4,412,055 Abstain 458,539 Broker Non-Votes 5,462,716 Proposal Four: Shareholder Proposal Regarding Simple Majority Vote. For 61,364,120 Against 6,382,985 Abstain 673,000 Broker Non-Votes 5,462,716
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 10.1 Consulting Agreement effective May 7, 2024 by and between IDEXX Laboratories, Inc. and James F. Polewaczyk 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIES, INC. Date: May 10, 2024 By: /s/ Sharon E. Underberg Sharon E. Underberg Executive Vice President, General Counsel and Corporate Secretary